ACTRIMS 2023 | Longitudinal studies to bring sNfL to MS clinical practice

Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses further steps needed to get serum neurofilament light chain (sNfL) ready for clinical use in multiple sclerosis (MS). Additional longitudinal studies are required to determine what changes are clinically meaningful to guide therapeutic decisions, monitoring, and prognosis. While NfL generally demonstrates good association with MS outcomes, what is going to be more informative are intra-individual changes in sNfL over time, which will also address some of the issues with reference values. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.